Table of Contents
Overview
MYC is one of a number of genes affected by aberrant somatic hypermutation in B-cell lymphomas, which complicates the interpretation of mutations at this locus.
Experimental Evidence
Driver mutations affecting this gene in DLBCL/FL/BL have been experimentally demonstrated to cause a gain of function (GOF).1
Relevance tier by entity
| Entity | Tier | Description |
|---|---|---|
| 1 | High-confidence BL gene | |
| 1 | High-confidence DLBCL gene | |
| 1 | High-confidence FL gene | |
| 2 | Role of MYC mutations in MZL requires confirmation | |
| 2 | Role of MYC mutations in PMBL requires confirmation |
Mutation incidence in large patient cohorts (GAMBL reanalysis)
DLBCL
| Entity | Collection | N | mutated | Incidence | 95% CI |
|---|---|---|---|---|---|
| DLBCL | GAMBL without Reddy | 1,089 | 69 | 0.0634 | [0.0489,0.0778] |
| DLBCL | GAMBL with Reddy | 2,088 | 131 | 0.0627 | [0.0523,0.0731] |
| DLBCL | BC | 231 | 13 | 0.0563 | [0.0266,0.086] |
| DLBCL | Dana-Farber | 303 | 20 | 0.0660 | [0.038,0.094] |
| DLBCL | NCI | 470 | 25 | 0.0532 | [0.0329,0.0735] |
| DLBCL | Reddy | 999 | 62 | 0.0621 | [0.0471,0.077] |
| DLBCL | DLBCL_ICGC | 85 | 11 | 0.1294 | [0.0581,0.2008] |
FL
| pathology | Collection | N | mutated | Incidence | CI |
|---|---|---|---|---|---|
| FL | GAMBL without Crouch | 642 | 6 | 0.0093 | [0.0019,0.0168] |
| FL | GAMBL with Crouch | 1,189 | 15 | 0.0126 | [0.0063,0.019] |
| FL | BC | 379 | 3 | 0.0079 | [0,0.0168] |
| FL | Kalmbach | 164 | 2 | 0.0122 | [0,0.029] |
| FL | Crouch | 547 | 9 | 0.0165 | [0.0058,0.0271] |
| FL | FL_ICGC | 99 | 1 | 0.0101 | [0,0.0298] |
BL
| pathology | Collection | N | mutated | Incidence | CI |
|---|---|---|---|---|---|
| BL | GAMBL without Panea | 309 | 197 | 0.6390 | [0.5856,0.6924] |
| BL | GAMBL without ICGC/Zhou | 320 | 202 | 0.6332 | [0.5806,0.6858] |
| BL | GAMBL with Panea | 410 | 254 | 0.6216 | [0.5748,0.6683] |
| BL | BLGSP | 219 | 145 | 0.6621 | [0.5995,0.7247] |
| BL | Zhou/ICGC | 90 | 52 | 0.5778 | [0.4757,0.6798] |
| BL | Panea | 101 | 57 | 0.5644 | [0.4677,0.6611] |
Mutation pattern and selective pressure estimates
Failed to render page: conflicting chdir during another chdir block
aSHM regions
| chr_name | hg19_start | hg19_end | region | regulatory_comment |
|---|---|---|---|---|
| chr8 | 128748352 | 128749427 | TSS | active_promoter |
MYC Hotspots
| Chromosome | Coordinate (hg19) | ref>alt | HGVSp |
|---|---|---|---|
| chr8 | 128750677 | C>A | P72T |
| chr8 | 128750677 | C>G | P72A |
| chr8 | 128750677 | C>T | P72S |
| chr8 | 128750677 | CC>TT | P72F |
| chr8 | 128750678 | C>G | P72R |
| chr8 | 128750678 | C>T | P72L |
| chr8 | 128750680 | A>G | T73A |
| chr8 | 128750681 | C>A | T73N |
| chr8 | 128750681 | C>T | T73I |
| chr8 | 128750681 | CC>AT | T73N |
| chr8 | 128750681 | CC>GT | T73S |
| chr8 | 128750681 | CC>TA | T73I |
| chr8 | 128750681 | CC>TG | T73M |
| chr8 | 128750681 | CC>TT | T73I |
| chr8 | 128750683 | C>G | P74A |
| chr8 | 128750683 | C>T | P74S |
| chr8 | 128750684 | C>T | P74L |
| chr8 | 128750686 | C>A | P75T |
| chr8 | 128750686 | C>G | P75A |
| chr8 | 128750686 | C>T | P75S |
| chr8 | 128750686 | CC>TT | P75F |
| chr8 | 128750687 | C>A | P75H |
| chr8 | 128750687 | C>G | P75R |
| chr8 | 128750692 | T>C | S77P |
| chr8 | 128750692 | T>G | S77A |
| chr8 | 128750693 | C>G | S77C |
| chr8 | 128750695 | C>T | P78S |
| chr8 | 128750696 | C>G | P78R |
Failed to render page: conflicting chdir during another chdir block
Expression
Failed to render page: conflicting chdir during another chdir block
References
1.
Freie B, Carroll PA, Varnum-Finney BJ, Ramsey
EL, Ramani V, Bernstein I, Eisenman RN. A germline point mutation in the
MYC-FBW7 phosphodegron initiates hematopoietic
malignancies. Genes Dev. 2024 Apr 17;38(5-6):253–272. PMCID: PMC11065175
2.
Duns
G, Viganò E, Ennishi D, Sarkozy C, Hung SS, Chavez E, Takata K, Rushton
C, Jiang A, Ben-Neriah S, Woolcock BW, Slack GW, Hsi ED, Craig JW,
Hilton LK, Shah SP, Farinha P, Mottok A, Gascoyne RD, Morin RD, Savage
KJ, Scott DW, Steidl C. Characterization of
DLBCL with a PMBL gene expression
signature. Blood. 2021 Jul 15;138(2):136–148.
3.
Jallades L, Baseggio L, Sujobert P, Huet S,
Chabane K, Callet-Bauchu E, Verney A, Hayette S, Desvignes JP, Salgado
D, Levy N, Béroud C, Felman P, Berger F, Magaud JP, Genestier L, Salles
G, Traverse-Glehen A. Exome sequencing identifies recurrent
BCOR alterations and the absence of KLF2,
TNFAIP3 and MYD88 mutations in splenic diffuse
red pulp small B-cell lymphoma.
Haematologica. 2017 Oct;102(10):1758–1766. PMCID: PMC5622860
4.
Johnston JM, Carroll WL. C-myc hypermutation in
Burkitt’s lymphoma. Leuk Lymphoma. 1992
Dec;8(6):431–439.
5.
Pasqualucci L, Neumeister P, Goossens T,
Nanjangud G, Chaganti RS, Küppers R, Dalla-Favera R. Hypermutation of multiple
proto-oncogenes in B-cell diffuse large-cell
lymphomas. Nature. 2001 Jul 19;412(6844):341–346.
